Epic二尖瓣位生物瓣的长期超声心动图数据、失败机制与再干预结局——一项大型观察性队列研究
本研究纳入单中心连续1397例二尖瓣置换使用Epic猪源异种生物瓣的患者,平均随访4.8年。Epic瓣血流动力学5年内稳定,5%患者因瓣膜失败接受再干预,10年免于全因再干预率88%、免于结构性瓣膜恶化再干预率92%。再干预类型对早期结局和中远期死亡率无显著影响。
要点
- Epic二尖瓣生物瓣血流动力学5年内稳定,结构性瓣膜恶化发生率低(1.9%)。
- 再干预主要因感染性心内膜炎和瓣叶撕裂(无钙化),10年免于全因再干预率88%。
- 再干预方式(redo-MVR与valve-in-valve)对早期结局和中远期死亡率无显著差异。
核心结论
- Epic二尖瓣生物瓣5年内血流动力学稳定,结构性瓣膜恶化和再干预发生率低,失败主要因感染性心内膜炎和瓣叶撕裂(无钙化)。
- 再干预类型对早期结局和中远期死亡率无影响。
研究设计与样本
- 单中心观察性队列研究,纳入1397例在本机构接受二尖瓣置换的连续患者,平均年龄72±8岁,46%为女性,平均随访4.8年。
- 临床、超声心动图、再干预和结局数据来自本机构前瞻性数据库或政府统计。
主要发现
- Epic瓣的跨瓣压差和有效瓣口面积在5年随访中保持稳定。
- 70例(5%)患者在中位随访3.0(0.7-5.4)年因人工瓣膜失败接受二尖瓣再干预,其中redo-MVR 38例(54%)、valve-in-valve 19例(27%)、瓣周漏(PVL)封堵12例(17%)、血栓清除1例。
- 失败机制包括结构性瓣膜恶化(SVD)27例(1.9%,均为瓣叶撕裂)、非SVD 16例(1.1%,其中PVL 15例、瓣膜血管翳1例)、感染性心内膜炎24例(1.7%)、血栓形成4例(0.3%)。
- 10年免于全因二尖瓣再干预率为88%,免于SVD相关二尖瓣再干预率为92%。
- 再干预的独立预测因素为年龄、基线心房颤动、初始二尖瓣病因和出院时中度或以上PVL(所有P≤0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Long-term echocardiographic reports on mitral valve (MV) porcine xenograft bioprosthesis (Epic) are lacking, and postreintervention outcomes of failed Epic are unknown. We aimed to assess the mechanisms and independent predictors of Epic failures and to compare short- and mid-term outcomes according to reintervention type. METHODS: We included consecutive patients (n = 1397; mean age: 72 ± 8 years; 46% female; mean follow-up: 4.8 years) who received the Epic during mitral valve replacement (MVR) at our institution. Clinical, echocardiographic, reintervention, and outcomes data were retrieved from our prospective institution's database or government statistics. RESULTS: Gradients and effective orifice area of the Epic were stable over 5-years follow-up. A total of 70 (5%) patients had a MV reintervention at median follow-up of 3.0 (0.7-5.4) years due to prosthesis failure, by redo-MVR (n = 38; 54%), valve-in-valve (n = 19; 27%), paravalvular leak (PVL) closure (n = 12; 17%), or thrombectomy (n = 1). Mechanisms of failure were 27 (1.9%) structural valve deterioration (SVD; all leaflet tear); 16 (1.1%) non-SVD (15 PVL, 1 pannus); 24 (1.7%) endocarditis; and 4 (0.3%) thrombosis. Freedom from all-cause and SVD-related MV reintervention at 10 years are 88% and 92%, respectively. Independent predictors of reintervention were age, baseline atrial fibrillation, initial MV etiology, and moderate or greater PVL at discharge (all P ≤ .05). Comparison of redo-MVR and valve-in-valve revealed no significant difference in early outcomes or mid-term mortality (all P ≥ .16). CONCLUSIONS: The Epic Mitral valve has stable hemodynamics through 5 years and is associated with low incidence of SVD and reintervention, mostly due to endocarditis and leaflet tear without calcification. Reintervention type had no influence on early outcomes and mid-term mortality.
引用
- Bernard J, Kalavrouziotis D, Salaun E, et al. Long-term echocardiographic data, mechanisms of failure, and reintervention outcomes of the Epic valve in mitral position-a large observational cohort. J Thorac Cardiovasc Surg. 2023. PMID: 37423547. doi:10.1016/j.jtcvs.2023.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。